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Abstract
Purpose Pulmonary hypertension (PH) is associated with a
poor outcome in chronic obstructive pulmonary disease
(COPD) and is diagnosed invasively. We aimed to assess the
diagnostic accuracy and prognostic value of non-invasive car-
diovascular magnetic resonance (CMR) models.
Methods Patients with COPD and suspected PH, who
underwent CMR and right heart catheter (RHC) were identi-
fied. Three candidate models were assessed: 1, CMR-RV
model, based on right ventricular (RV) mass and interventric-
ular septal angle; 2, CMR PA/RV includes RV mass, septal
angle and pulmonary artery (PA) measurements; 3, the Alpha
index, based on RVejection fraction and PA size.
Results Of 102 COPD patients, 87 had PH. The CMR-PA/RV
model had the strongest diagnostic accuracy (sensitivity 92%,
specificity 80%, positive predictive value 96% and negative
predictive value 63%, AUC 0.93, p<0.0001). Splitting RHC-
mPAP, CMR-RVand CMR-PA/RV models by 35mmHg gave
a significant difference in survival, with log-rank chi-squared
5.03, 5.47 and 7.10. RV mass and PA relative area change
were the independent predictors of mortality at multivariate
Cox regression (p=0.002 and 0.030).
Conclusion CMR provides diagnostic and prognostic infor-
mation in PH-COPD. The CMR-PA/RV model is useful for
diagnosis, the RV mass index and PA relative area change are
useful to assess prognosis.
Key Points
• Pulmonary hypertension is a marker of poor outcome in
COPD.
• MRI can predict invasively measured mean pulmonary ar-
tery pressure.
• Cardiac MRI allows for estimation of survival in COPD.
• Cardiac MRI may be useful for follow up or future trials.
• MRI is potentially useful to assess pulmonary hypertension
in patients with COPD.
Keywords Pulmonary Hypertension . Cardiac . Magnetic
Resonance Imaging . Chronic Obstructive Pulmonary
Disease . Cor Pulmonale
Background
Pulmonary hypertension is a predictor of death and
hospitalisation [1–5] in patients with chronic obstructive pul-
monary disease (COPD). Patients with pulmonary hyperten-
sion in COPD, as defined by a mean pulmonary artery pres-
sure (mPAP) of ≥25mmHg have a 5-year survival rate of 36%
[6]. A number of studies in patients with severe COPD have
shown that mild pulmonary hypertension is common: a recent
study in patients with severe COPD referred for lung volume
reduction surgery demonstrating pulmonary hypertension at
right heart catheter in 50% [7, 8]. More recently, with the
advent of therapies for other forms of pulmonary hypertension
there has been increasing interest in the subset of lung disease
patients with severe (previously called Bout of proportion^)
pulmonary hypertension, defined as an mPAP ≥35 mmHg or
mPAP ≥35 mmHg with cardiac index ≤2.0 [9], where a car-
diovascular limitation to exercise, rather than respiratory
* C. S. Johns
c.johns@sheffield.ac.uk
1 Academic Unit of Radiology, C floor, Royal Hallamshire Hospital,
Glossop Rd, Sheffield S10 2JF, UK
2 Sheffield Pulmonary Vascular Disease Institute, Sheffield, UK
3 Insigneo, Institute of In-Silico Medicine, Sheffield, UK
Eur Radiol
https://doi.org/10.1007/s00330-017-5143-y
limitation exists [10]. This raises the possibility that pulmo-
nary vascular therapies may improve symptoms and outcome
in this patient group [11].
The gold standard for diagnosis of pulmonary hypertension
is right heart catheter (RHC), however, this is an invasive test
[12]. As such, patients are screened for pulmonary hyperten-
sion with echocardiography, but unfortunately, this is less ac-
curate in COPD where pulmonary artery pressure, when mea-
sured, is often overestimated [13, 14]. A non-invasive method
for estimating mPAP in COPD patients would, therefore, be
useful to help diagnose PH, in prognostication and for possi-
ble assessment of treatment response or follow-up in clinical
trials.
Several predictive cardiac magnetic resonance (CMR) im-
aging models have been proposed for estimation of pulmo-
nary artery pressure [15–17]. The predictive value of these
MR derived imaging models in a population of patients with
suspected pulmonary hypertension in COPD remains un-
known. The aim of this study was to assess the diagnostic
accuracy and the prognostic value of these published models
of non-invasive mPAP prediction using cardiovascular MRI.
Materials and Methods
All consecutive patients who underwent MRI at a pulmonary
hypertension referral centre [18] from April 2012 to October
2015 with suspected pulmonary hypertension were assessed
for inclusion. Inclusion criteria were a formal diagnosis of
COPD (according to standard criteria), as per the ASPIRE
(Assessing the Spectrum of Pulmonary hypertension
Identified at a REferral centre) registry [18]. Patients were
assessed for either obstructive spirometry (defined as FEV1/
FVC ratio of ≤0.70) or qualitative CT evidence of emphyse-
ma, as per standard radiological practice [19]. Any patients
without RHC and MRI within 90 days were excluded. Ethical
approval was granted from a local ethics committee for this
retrospective study, written consent was waived (ref c06/
Q2308/8).
Image Acquisition
Cardiac MRI was performed in a pulmonary hypertension
tertiary referral centre [18], on a GE HDx 1.5-T whole body
scanner (GE Healthcare, Milwaukee, WI, USA), using an 8-
channel cardiac coil, with the patient supine. Four-chamber
(4Ch) and short axis (SA) cine images were acquired using a
retrospectively cardiac gated multi-slice steady-state free pre-
cession (SSFP) sequence. A stack of axial images in the SA
plane with slice thickness of 8 mmwith a 2 mm inter-slice gap
or 10 mmwith no inter-slice gap were acquired, covering both
ventricles from base to apex. The SSFP sequence parameters
were: TR 2.8 ms, TE 1.0 ms, flip angle 50°, field of view
48x43.2, 256x256 matrix, 125 kHz bandwidth, and slice
thickness 8 to 10 mm. This cardiac MRI scan protocol takes
approximately 40 min to perform.
Image Analysis and Metrics
MR images were manually analysed by DC (a cardiac MRI
radiographer of 9 years cardiac MRI experience) on a GE
Advantage Workstation 4.4 and GE Advantage Workstation
ReportCard software, with the observer blinded to all clinical
information and other investigations. Left and right ventricular
end-diastolic volume, end-systolic volume, right and left ven-
tricular stroke volume andmass were calculated (all indexed to
body surface area), right and left ventricular ejection fraction,
ventricularmass index (RVmass divided by LVmass) [20] and
interventricular septal angle were measured as previously de-
scribed [15]. Right and left ventricular ejection fractions were
calculated as (end diastolic volume minus end-systolic vol-
ume) divided by end diastolic volume. Maximal and minimal
PA areas were manually traced, and relative area change was
defined by the following equation: RAC= (maximum area-
minimum area/minimum area) [21]. Reproducibility metrics
for these cardiac MRI metrics for DC and AJS have been
previously published [22]. Please see Fig. 1 for a diagram of
the key imaging metrics that were measured.
CMR image based models
Previously published parametric models, developed for diag-
nostic and prognostic assessment in PH, were derived from
cardiac MRI metrics:
1. The CMR-RV model is based on ventricular mass index
and interventricular septal angle: mPAP = –4.6 + (inter-
ventricular septal angle x 0.23) + (ventricular mass index
x 16.3), see Fig. 1 (A and B). This model was developed
in a cohort of 64 treatment naïve patients with suspected
pulmonary hypertension in a tertiary referral centre. In a
derivation cohort of 64 patients with suspected pulmonary
hypertension, this showed good correlation with right
heart catheter measured mPAP and strong diagnostic ac-
curacy. The published threshold of ≥32 mmHg had 87%
sensitivity and 90% specificity for the presence of all
causes of pulmonary hypertension [15].
2. The PA/RV model is similar to the CMR-RV model
(above), with the addition of basic function metrics of
the pulmonary artery: CMR-PA/RV = -21.806 + (inter-
ventricular septal angle x 0.31) + (ventricular mass index
x 11.5) + (diastolic pulmonary artery area x 0.01) – (PA
relative area change x 0.22), see Fig. 1 (A, B, C and D).
This model was derived in 247 patients with suspected
pulmonary hypertension patients andwas predictive of pul-
monary hypertension in a separate prospective cohort of
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115 patients, with an area under the receiver operator curve
of 0.92 [16].
3. The alpha index comprises both functional and structural
information, utilising right ventricular function along with
pulmonary artery size: Alpha index = minimum PA area/
RVejection fraction. This model was assessed in a cohort
of 185 patients, with an area under ROC curve of 0.95
[17].
The diagnostic cut-off for pulmonary hypertension for
CMR-RV was ≥32 and alpha index ≥7.2, as published in the
literature [15–17]. CMR-PA/RV does not have a published
threshold, so we used a threshold of ≥25, as this mirrors the
threshold of invasively measured mPAP at right heart
catheterisation.
Right Heart Catheterisation
Right heart catheterisation was performed using a balloon
tipped 7.5 Fr thermodilution catheter (Becton-Dickinson,
Franklin Lakes, NJ, USA). Pulmonary hypertension was de-
fined as a resting mPAP ≥25 mmHg and severe pulmonary
hypertension as a resting mPAP ≥35 mmHg. Cardiac output
was calculated using thermodilution.
Statistics
Pearson’s correlation between CMR models and RHC-mPAP
were calculated. The relative accuracy of the models was
assessed using Bland-Altman plots. Diagnostic accuracy was
calculated from the 2x2 contingency table to calculate sensitiv-
ity, specificity, negative predictive value and positive predictive
value. Receiver operating characteristic (ROC) curves were
constructed and the area under the ROC curve (AUC) recorded.
The interval from CMR until all cause death or census was
regarded as the follow-up period. The census was performed on
25/02/2016. Log-log plots were visually inspected to ensure lin-
earity with outcome data. Survival analysis was performed using
univariate and multivariate Cox proportional hazards regression.
In order to allow for comparison between each metric, this was
Fig. 1 Diagram showing the
methodology of calculation of the
cardiac MRI metrics. Pulmonary
artery relative area change (a)
taken from cine images taken at
the level of the pulmonary trunk,
perpendicular to the main
pulmonary artery; septal angle (b)
taken as the angle made between
the insertion points of the RV to
the mid septum on the end-
systolic image from the short axis
stack; and (c) ventricular mass
index taken by segmentation of
the muscle mass of the left and
right ventricle on the stack of
images taken in the short axis
plane
Fig. 2 Patient selection
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performed with each variable standardised as the z score for the
population studied. Multivariate analysis was performed in a
forward direction, for all variables with a statistically significant
association with mortality on univariate analysis.
Kaplan-Meier plots were generated for each model and
RHC measured mPAP, dichotomised by a value of 35, and
Chi square values were calculated using the Log rank test, as
this is the threshold value for severe pulmonary hypertension
[9]. Statistical analysis was made using SPSS 22 (IBM,
Chicago, IL, USA) and graphs were created using GraphPad
Prism 7 (GraphPad Software, San Diego, CA, USA). A p-
value of <0.05 was considered statistically significant.
Results
A total of 1864 patients were referred to the pulmonary hy-
pertension centre during the period studied and underwent
Table 1 Patient demographics,
mean with standard deviation
with ANOVA p-value between no
PH, mild PH and severe PH
All patients No PH PH Severe PH p-value
(ANOVA)
Number 102 15 18 69
Clinical Demographics
Age (years) 67 (12) 59 (17) 67 (12) 69 (9) 0.012
Sex (F/M)
WHO functional class (II,III,IV)
ISWT (m) 174 (169) 432 (264) 141 (101) 121 (87) <0.001
Baseline catheter data
mPAP (mmHg) 40 (12) 21 (3) 31 (3) 47 (8) <0.001
mRAP (mmHg) 11 (6) 6 (2) 8 (3) 11 (7) 0.056
PAWP (mmHg) 12 (4) 10 (3) 12 (3) 13 (4) 0.013
CI (Litre/m2) 2.8 (0.9) 3.1 (0.7) 3.2 (0.9) 2.6 (0.9) 0.005
PVRI (Dyne.s) 3.7 (0.9) 3.1 (0.7) 3.2 (0.9) 2.6 (0.9) <0.001
SvO2 (%) 65 (9) 72 (8) 69 (5) 62 (9) <0.001
Days RHC to MR 5 (15) 5 (19) 5 (13) 5 (14) 0.989
Spirometry n=89 n=9 n=17 n=63
FEV1 (% Pred) 66 (24) 76 (24) 58 (15) 66 (25) 0.165
FVC (% Pred) 85 (22) 92 (20) 77 (15) 87 (24) 0.155
FEV1/FVC 0.55 (0.15) 0.63 (0.20) 0.51 (0.10) 0.55 (0.15) 0.179
TLCO (% Pred) 30 (22) 80 (31) 33 (15) 21 (9) <0.001
Cardiac MRI
RV EDV index 89 (35) 72 (30) 70 (32) 97 (34) 0.002
RV ESV index 56 (31) 36 (18) 37 (26) 66 (30) <0.001
RVEF 40 (14) 51 (8) 51 (11) 35 (12) <0.001
RV mass index
LV EDV index 55 (18) 62 (10) 63 (18) 52 (19) 0.026
LV ESV index 20 (18) 19 (6) 20 (10) 20 (12) 0.921
LVEF 64 (12) 69 (10) 69 (9) 61 (12) 0.014
PA RAC 10 (8) 16 (14) 12 (8) 8 (6) 0.008
VMI 0.43 (0.28) 0.28 (0.11) 0.28 (0.17) 0.51 (0.31) 0.001
IVS angle 165 (24) 134 (10) 152 (14) 174 (20) <0.001
Black blood score 3 (1) 1 (1) 2 (1) 3 (1) <0.001
Alpha-index 25 (14) 13 (6) 16 (6) 30 (14) <0.001
CMR-RV 41 (9) 33 (4) 35 (5) 44 (9) <0.001
CMR-PA/RV 35 (9) 23 (5) 30 (5) 39 (7) <0.001
PH: pulmonary hypertension, WHO: World Health Organisation, ISWT: Incremental shuttle walk test, FEV1:
Forced expiratory volume in 1 s, RVC-mPAP: right heart catheter measured mean pulmonary artery pressure,
mRAP: mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: cardiac index, PVRI: pulmo-
nary vascular resistance index, SvO2: mixed venous oxygen saturation, FVC: forced vital capacity, TLCO:
transfer factor for carbon monoxide, RHC: right heart catheter, MRI: magnetic resonance imaging
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right heart catheterisation: of these 145 had a documented
diagnosis of COPD from a respiratory specialist. One hundred
and two had MRI and RHC within 90 days so were included
in the study. There were 87 patients with pulmonary hyper-
tension (69 of these had severe pulmonary hypertension) and
15 patients without pulmonary hypertension (please see Fig. 1
for the patient diagnostic pathway). Figure 2 shows the flow of
patients within the diagnostic pathway. There were 24 with
GOLD severity 1, 40 with GOLD severity 2, 18 with GOLD
severity 3 and seven with GOLD severity 4; 13 patients did
not have spirometry results available for analysis. Of the 102
cases of COPD included in the study, 75 had spirometric ev-
idence of airflow limitation (FEV1/FVC ratio <0.7), and the
remaining 17 had evidence of emphysema on CT. Table 1
shows the patient demographics and clinical characteristics
for the whole group and split into no PH (mPAP <25
mmHg), PH (mPAP 25 to ≤35 mmHg) and severe PH
(mPAP ≥35 mmHg).
Diagnostic accuracy
Table 2 shows the univariate correlations of CMR imaging
metrics: RV end diastolic volume index, RV end systolic vol-
ume index, RV ejection fraction, RV mass, PA diastolic area
and relative area change, ventricular mass index, interventric-
ular septal angle septal angle, average velocity and black
blood score all showed statistically significant correlations
with RHC mPAP. All of the models showed strong correla-
tions with RHC measured mPAP, with p-values <0.0001. The
CMR-PA/RV model showed stronger correlation with mPAP
than the individual quantitative measurements alone. A scatter
plot of the MRI models against RHC-mPAP is given in Fig. 3.
The models all showed a stronger correlation with mPAP in
the patients with mPAP <35 mmHg (r- and p-values for PA-
RV were 0.550 and 0.001, CMR-PA/RV 0.653 and <0.001
and alpha 0.341 and 0.052) than in the patients with mPAP
≥35 mmHg (r- and p-values for PA-RV were 0.431 and
<0.001, CMR-PA/RV 0.407 and 0.001 and alpha 0.210 and
0.083).
Bland-Altman plots were also created to assess the accura-
cy of the models against RHC-mPAP (Fig. 4), this was not
performed for alpha index as it was not designed to directly
assess mPAP. Bland-Altman analysis showed modest accura-
cy for CMR-RV (bias -5.2%, limits of agreement -51.2 to
40.8%) and CMR-PA/RV models (bias 12.2% and limits of
agreement -30.7 to 55.0%). Table 2 shows the correlation of
the CMR models against RHC mPAP. Figure 5 shows the
ROC curves for the three CMR models. CMR-PA/RV and
CMR-RV had the largest AUC values, 0.93 (95% confidence
interval 0.86-1.0) and 0.91 (95% confidence interval 0.84-
0.97), respectively, and alpha index also showed good diag-
nostic accuracy with AUC 0.837 (95% confidence interval
0.74-0.94). The sensitivity and specificity of the CMR-PA/
RV model was 92% and 80%, CMR-RV model 90% and
79%, and the alpha index 100% and 13%, respectively
(Table 3).
Outcome
During a mean follow up period of 1.5 years (standard devi-
ation 0.9) there were 33 deaths. Table 4 gives the scaled uni-
variate Cox proportional hazards regression results for patient
demographics, RHC and CMRmeasurements. Age, sex, walk
distance FEV1 percent predicted, FVC percent predicted and
FEV1/FVC ratio were not univariate predictors of mortality.
PA relative area change, right ventricular mass index, ventric-
ular mass index, interventricular septal angle and RV end-
diastolic volume index were univariate predictors of mortality
(p=0.009, p<0.001, p=0.002 and p=0.023, respectively). RHC
measured mPAP was a strong predictor of mortality
(p=0.004), as were the CMR-RV and CMR-PA/RV models
(p=0.002 and p=0.012, respectively). There was a statistically
significant difference in survival when the population was
split by a threshold of 35 mmHg for RHC-mPAP, CMR-RV
and CMR-PA/RVmodels, with a log rank chi squared of 5.03,
5.47 and 7.10, respectively (see Fig. 6 and Table 5). On mul-
tivariate analysis (performed on all univariate predictors of
Table 2 CMR imaging metrics and MRI model correlations with
mPAP
Correlation with mPAP
R p-value
RVEDV index 0.377 <0.0001
RVESV index 0.482 <0.0001
RVEF -0.585 <0.0001
RV mass 0.372 <0.0001
LVEDV index -0.304 0.002
LVESV index -0.029 0.772
LVEF -0.221 0.026
PA diastolic area 0.401 <0.0001
PA RAC -0.344 <0.0001
VMI 0.470 <0.0001
IVS angle 0.710 <0.0001
Average PA velocity -0.428 <0.0001
Black blood score 0.603 <0.0001
CMR-RV 0.689 <0.0001
CMR-PA/RV 0.732 <0.0001
Alpha index 0.527 <0.0001
RVEDV: right ventricular end-diastolic volume, RVESV: right ventricu-
lar end-systolic volume, RVEF: right ventricular ejection fraction, RV:
right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV:
left ventricular end-systolic volume, LVEF: left ventricular ejection frac-
tion, PA: pulmonary artery, PA RAC: pulmonary artery relative area
change, VMI: ventricular mass index, IVS: interventricular septum
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outcome for demographics, right heart catheter and cardiac
MRI), right ventricular mass index and PA relative area
change were statistically significant, with scaled Cox multi-
variate hazard ratios 1.549 (95% CI 1.172-2.047, p=0.002)
and 0.561 (95% CI 0.333-0.946, p=0.030), respectively.
Discussion
This study demonstrates that CMR models can be used to
assess for the presence of pulmonary hypertension in COPD
with good diagnostic accuracy, whilst also providing prognos-
tic information similar to right heart catheterisation. This data
supports the potential use of CMR in the non-invasive assess-
ment of suspected pulmonary hypertension in patients with
COPD. We have shown that single measurements from cardi-
ac MRI (most notably septal angle) correlate strongly with
right heart catheter measured mPAP. A model which includes
measurements from the right ventricle, the diagnostic accura-
cy is slightly reduced, but inclusion of basic measurements
of pulmonary arterial structure and function increases the
accuracy of predicted mPAP and, therefore, the presence
of pulmonary hypertension. Therefore, we recommend the
use of CMR-PA/RV model in the diagnosis of pulmonary
hypertension in patients with COPD. In the presence of
COPD, right ventricular mass index and PA relative area
change are the strongest predictors of outcome, but further
work to develop prognostic thresholds is required.
Studies performed primarily in patients with pulmonary
arterial hypertension have shown that structural and functional
indices of the right ventricle (RV end diastolic volume index,
RVend-systolic volume index, RVejection fraction, RV mass,
interventricular septal angle) and pulmonary artery (PA area,
PA relative area change and black blood score) correlate with
RHC measured mPAP. Inter- and intra-observer reproducibil-
ity data for these cardiac MRI metrics for DC and AJS have
been previously published. RVend-diastolic and systolic mea-
surements had excellent inter-observer reproducibility (ICC
0.959 and 0.991) and pulmonary artery relative area change
had high inter-observer reproducibility (ICC 0.891). Right
ventricular ejection fraction also had high inter-observer re-
producibility (ICC 0.957) [22]. We and others, have shown
that we can further develop predictive equations using MR
metrics to estimate measurements made at cardiac
Fig. 3 Scatter plots showing correlations of each MRI model with right heart catheter measured mPAP
Fig. 4 Bland-Altman plots
showing accuracy of models
against RHC-mPAP
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catheterisation. However, to date there is very little data on the
use of MR imaging as a diagnostic and prognostic tool in
patients with COPD and suspected pulmonary hypertension.
In this study we have shown that these structural and func-
tional indices of the right ventricle and pulmonary artery cor-
relate with right heart catheter measured mean pulmonary ar-
terial pressure: with pulmonary artery relative area change,
ventricular mass index and interventricular septal angle hav-
ing the strongest correlations. We have shown that the use of
CMR-PA/RVand CMR-RVmodels, improve the prediction of
mPAP and also the diagnostic accuracy of quantitative CMR
measures.
The alpha model showed good correlation with mPAP, but
had a low diagnostic accuracy: this model suffered from a
diagnostic threshold that was too low for this cohort, signifi-
cantly reducing its specificity. Changing the threshold of the
alpha index to 16 increased the diagnostic accuracy of this
model to 77% sensitivity and 80% specificity. This inaccuracy
may be related to the measurement of right ventricular ejection
fraction, particularly the reproducibility between different
centres. In the original paper, it was not described how the
right ventricular endocardial contours were measured, specif-
ically, whether the papillary muscles and RV trabeculations
were included, which may potentially add a bias into the
calculation.
Pulmonary hypertension, confirmed by right heart catheter,
has been recognised for many years as a marker of disease
severity in COPD. In this study we have shown that cardiac
MRImeasured right ventricular mass and therefore ventricular
mass index, along with pulmonary artery relative area change
are significant predictors of mortality on univariate analysis.
Fig. 5 ROC curve for the diagnosis of pulmonary hypertension
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However, by using CMR derived parametric models, particu-
larly the CMR-RVmodel which combine these CMRI derived
measures, we can improve the prediction of outcome in
COPD patients on multivariate analysis. These models may
be further improved with novel imaging biomarkers in pulmo-
nary hypertension assessment. One such marker is the 4D
flow assessment of the life of vortices within the pulmonary
artery, which has been shown to have a very high correlation
with mPAP (r2 0.95) [23].
A potential source of error arises from the use of MR
models, which were developed for use in a cohort of all causes
of pulmonary hypertension and not validated in specific sub-
groups, such as PH-COPD in this case. We feel that it is likely
that the findings of a raised interventricular septal angle and
Table 4 Univariate Cox
proportional hazards regression
analysis for survival
Cox univariate hazard ratio 95% confidence interval p-value
Demographics
Age 1.424 0.936 2.166 0.098
Sex 0.781 0.388 1.57 0.487
WHO functional status 1.45 1.031 2.039 0.033
Walk distance 0.475 0.167 1.354 0.164
FVC % pred 1.221 0.835 1.785 0.304
FEV1 % pred 1.399 0.928 2.108 0.109
FEV1/FVC 1.244 0.85 1.82 0.262
TLCO % pred 0.593 0.19 1.852 0.369
Right heart catheter
mPAP 1.74 1.198 2.526 0.004
mRAP 1.297 0.873 1.927 0.199
PAWP 0.933 0.651 1.338 0.707
CI 0.847 0.566 1.268 0.421
PVRI 1.384 1.034 1.853 0.029
SvO2 0.857 0.59 1.245 0.418
Cardiac MRI
RV EDV index 1.381 1.013 1.882 0.041
RV ESV index 1.338 0.981 1.824 0.066
RVEF 0.784 0.548 1.122 0.183
RV mass index 1.673 1.303 2.148 <0.001
LV EDV index 0.759 0.494 1.166 0.209
LV ESV index 0.766 0.478 1.228 0.269
LVEF 1.077 0.756 1.535 0.681
PA RAC 0.543 0.343 0.859 0.009
VMI 1.417 1.135 1.768 0.002
IVS angle 1.48 1.055 2.075 0.023
Black blood score 1.377 0.925 2.05 0.115
Average PA velocity 1.018 0.697 1.484 0.928
Alpha-index 1.19 0.858 1.65 0.297
CMR-RV 1.565 1.175 2.083 0.002
CMR-PA/RV 1.59 1.108 2.282 0.012
WHO: World Health Organisation, FEV1: Forced expiratory volume in 1 s, FVC: Forced vital capacity, RHC:
right heart catheter, mPAP: right heart catheter measured mean pulmonary artery pressure, mRAP: mean right
atrial pressure, PAWP: pulmonary artery wedge pressure, CI: cardiac index, PVRI: pulmonary vascular resistance
index, SvO2: mixed venous oxygen saturation, CMR: cardiopulmonary magnetic resonance, RVEDV: right
ventricular end-diastolic volume, RVESV: right ventricular end-systolic volume, RVEF: right ventricular ejection
fraction, RV: right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic
volume, LVEF: left ventricular ejection fraction, PA RAC: pulmonary artery relative area change, VMI:
ventricular mass index, IVS: interventricular septum, CMR-RV: right ventricle based cardiopulmonary magnetic
resonance image model, CMR-PA/RV: pulmonary artery and right ventricle based cardiopulmonary magnetic
resonance image model
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ventricular mass index are likely to occur most subgroups of
pulmonary hypertension (with the exception of left heart dis-
ease) as they are related to the pressure differential between
the left and right ventricles. The measures of pulmonary arte-
rial structure and function (size and relative area change) are
likely to be transferable across subgroups, as they are markers
of pulmonary vascular compliance and remodelling. We,
therefore, feel that it reasonable to use these models in specific
sub-groups of pulmonary hypertension, although validation,
such as in this paper, would be useful. The models that are
used in this paper use parameters that are stated with a degree
of precision (for example an offset of 21.806 for CMR-PA/
RV), likely more than is required for this purpose. We have
maintained the equations in the published form to reduce any
bias in the calculations, but it is likely that fewer decimal
places could be used for these parameters for the prediction
of outcome and the presence of pulmonary hypertension in
COPD.
Currently, RHC is the gold standard test for the assessment
of pulmonary hypertension and is used to assess prognosis in
suspected COPD-PH cases. The ability to use non-invasive
CMR models in this patient group may avoid the need for
RHC, as we have shown CMR to be as good in the assessment
of prognosis. The strong correlation of CMR imaging models
with RHCmPAP suggest it may also have a role in follow-up,
and also in assessment of treatment response in possible future
trials assessing vasodilator response in COPD-PH. The role of
cardiac MRI in COPD is further strengthened as this is a
cohort of patients in which echocardiography is challenging.
In the presence of COPD echocardiography has a relatively
high rate of non-diagnostic quality studies. It has a good neg-
ative predictive value, but a poorer positive predictive value
[14]. In patients with a normal right ventricle and predicted
systolic pulmonary artery pressure (estimated from the tricus-
pid regurgitant jet velocity using the Bernoulli equation) pul-
monary hypertension is highly unlikely. The main role for
cardiac MRI in patients with COPD, therefore, probably lies
in the group of patients with high estimated systolic pulmo-
nary artery pressures or non-diagnostic scans. This may be at
diagnosis, as studied in this paper, or potentially at follow-up.
The non-invasive estimation of mPAP has multiple other
potential uses, beyond prognosis in COPD, although these
have not been addressed in this paper. In advanced COPD
patients considered for lung volume reduction surgery
(LVRS), severe pulmonary hypertension is considered a
contraindication [24], so the non-invasive assessment of
mPAP on MR would be a useful tool in patient selection.
Furthermore, left or right ventricular dysfunction is consid-
ered a relative contraindication to LVRS [24], and can be
assessed at the same CMR sitting. In COPD patients with
pulmonary hypertension there is evidence that outcome
may be improved if treated with lung transplantation over
LVRS [25], assessment of mPAP could be performed in the
same sitting as a ventilation study in the preoperative as-
sessment of LVRS or transplant candidates [26, 27],
allowing for the assessment of the best surgical option and
the best target in the lung.
This study is limited by its single centre, retrospective
design, at a tertiary pulmonary hypertension referral centre
where the severity of pulmonary hypertension is more se-
vere. The results, therefore, represent a biased population,
as the patients have been screened by echocardiography
and excessive symptoms for the presence of pulmonary
hypertension before referral (the vast majority of patients
with COPD are managed in primary care). This has resulted
in a smaller proportion of non-pulmonary hypertension pa-
tients than would be present in a general population of
COPD; however, in the absence of a prospective trial, this
is difficult to overcome. Furthermore, the assessment of the
presence of COPD in the population relied upon the accu-
rate documentation of a clinical diagnosis of COPD. This
likely resulted in a lower proportion of patients being identi-
fied, but is likely to be more robust than using either spirom-
etry or CT defined emphysema alone. Despite this, we feel
that these tools are valid for the assessment of patients who are
referred to a pulmonary hypertension centre regarding the
presence of pulmonary hypertension and prognosis, as this is
the population that was studied. It may be that more specific
diagnostic thresholds would be suitable for use in the general
COPD population.
Fig. 6 Kaplan-Meier survival tables, all dichotomised by 35
Eur Radiol
Conclusion
The use of the CMR-PA/RV model, derived from cardiovas-
cular magnetic resonance imaging in the assessment of COPD
allows for accurate, non-invasive estimation of pulmonary
artery pressure and the presence of pulmonary hypertension.
Right ventricular mass index and pulmonary artery relative
area change are most predictive of outcome.
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